20/20 Biolabs Inc.
AIDX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AIDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIDX
20/20 Biolabs Inc. (AIDX) is a diagnostics company developing and commercializing cancer screening and longevity tests, with minimal revenue and a history of operating losses.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
20/20 Biolabs Inc. (AIDX) is a diagnostics company developing and commercializing cancer screening and longevity tests, with minimal revenue and a history of operating losses.
- Cash and equivalents of $4.5M as of 2026-06-30 [sec].
- Total revenue of $0.7M and net loss of -$1.5M as of 2026-06-30 [sec].
- Shareholders' equity of $0.4M as of 2026-06-30 [sec].
- Launched a longevity test during the first quarter of 2026 [sec_mda · as of 2026-05-20].
- Net loss decreased to $3.7M for 2025 from $5.6M in 2024, a 32.65% reduction [sec_mda · as of 2026-03-31].
What works
- Net loss decreased by 32.65% year-over-year from 2024 to 2025, indicating improving cost management [sec_mda · as of 2026-03-31].
- R&D expenses decreased 53% in 2025 compared to 2024, partly because prior-year studies (NCI MCED validation, capillary blood validation) were completed successfully and benefit the company going forward [sec_mda · as of 2026-03-31].
- The company launched a new longevity test in Q1 2026, expanding its product pipeline beyond cancer screening [sec_mda · as of 2026-05-20].
What to weigh
- The company has incurred recent operating losses and management expects these may continue in the near term [sec_mda · as of 2026-03-31].
- Cash and equivalents of $1.0M as of December 31, 2025, were low relative to operating needs; subsequent to that date the company raised $5M through a private placement and convertible debt [sec · filed 2026-04-06].
- The company's success depends heavily on its cancer screening and longevity tests, and failure to generate sufficient operating revenue could force closure or additional dilutive financing [sec · filed 2026-04-06].
- Shareholders' equity was only $0.4M as of 2026-06-30, indicating a thin equity base [sec].
From the filings
Quoted directly from source documents.
Net loss decreased from 2024 to 2025
“we generated a net loss of $3,738,821 for the year ended December 31, 2025, as compared to $5,551,667 for the year ended December 31, 2024, a decrease of $1,812,846, or 32.65%”
SEC MD&A · March 31, 2026
Longevity test launched in Q1 2026
“further development of our longevity test which we launched during the first quarter of 2026”
SEC MD&A · May 20, 2026
Cash and equivalents as of Dec 31, 2025
“As of December 31, 2025, we had cash and cash equivalents of $1,025,987”
SEC MD&A · March 31, 2026
Subsequent financing raised
“subsequent to December 31, 2025 we have raised additional funding through a private placement of $5 million and convertible debt and bridge fi”
SEC filings · April 6, 2026
Risks & what to watch (3)›
Key risks
- Going concern risk — The company has incurred recent operating losses and may need additional capital to continue operations [sec_mda · as of 2026-03-31].
- Dependence on test sales — Success depends heavily on cancer screening and longevity tests; failure to generate sufficient revenue could force closure [sec · filed 2026-04-06].
- Dilution from financing — Additional equity sales would dilute existing stockholders; debt financing would increase obligations [sec · filed 2026-04-06].
What to watch
- Cash burn rate and need for further financing [sec_mda · as of 2026-03-31].
- Commercial adoption and revenue growth of the newly launched longevity test [sec_mda · as of 2026-05-20].
- Progress in scaling sales and marketing for diagnostic tests [sec · filed 2026-04-06].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run 20/20 Biolabs Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available 20/20 Biolabs Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
23.3 months
D/E 1.83 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$50K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 16,227 | $31K |
| xtx topco ltd | 10,329 | $19K |
| toth financial advisory corp | 157 | $296 |
Short Interest
as of May 12, 2026- % of float
- 0.4%
- Days to cover
- 0.5
- Shares short
- 33,116
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for 20/20 Biolabs Inc.?
20/20 Biolabs Inc. (AIDX) is a diagnostics company developing and commercializing cancer screening and longevity tests, with minimal revenue and a history of operating losses.
Who is the CEO of 20/20 Biolabs Inc.?
Mr. Jonathan Cohen is the chief executive officer of 20/20 Biolabs Inc. (AIDX).
Where is 20/20 Biolabs Inc. headquartered?
20/20 Biolabs Inc. (AIDX) is headquartered in Gaithersburg, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.